MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-04-2025
InfuSystem Holdings Operating Income 2011-2026 | INFU
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income InfuSystem Holdings
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.65 M | 2.82 M | 8.83 M | 3.52 M | 415 K | -3.81 M | 974 K | 7.28 M | 9.33 M | 5.9 M | 2 M | -66.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 9.33 M | -66.4 M | -2.29 M |
Quarterly Operating Income InfuSystem Holdings
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3.81 M | 3.78 M | 618 K | - | 3.26 M | 1.86 M | -845 K | - | 1.7 M | 1.25 M | -107 K | - | 943 K | 207 K | -525 K | - | -351 K | 696 K | 873 K | - | 3.25 M | 4.51 M | 33 K | - | 1.66 M | 971 K | -420 K | - | -95 K | -204 K | 588 K | - | 560 K | -1.09 M | -1.97 M | - | 576 K | 438 K | 414 K | 2.49 M | 2.33 M | 1.08 M | 1.38 M | - | 2.44 M | 2.34 M | 1.78 M | - | 1.92 M | 861 K | 652 K | - | 921 K | 29 K | -513 K | - | -22.5 M | -43.4 M | 227 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.51 M | -43.4 M | -469 K |
Operating Income of other stocks in the Medical instruments industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AtriCure
ATRC
|
-9.45 M | $ 28.22 | -2.32 % | $ 1.35 B |  USA |
 |
Baxter International
BAX
|
-308 M | $ 17.24 | 3.61 % | $ 8.84 B | USA |
 |
Atrion Corporation
ATRI
|
22.6 K | - | - | $ 810 M | USA |
 |
BioLife Solutions
BLFS
|
-7.13 M | $ 19.71 | 3.03 % | $ 908 M | USA |
 |
Ekso Bionics Holdings
EKSO
|
-13.3 M | $ 8.73 | -3.64 % | $ 21.2 M | USA |
 |
Alcon
ALC
|
580 M | $ 77.31 | 3.54 % | $ 40.4 B |  Schweiz |
 |
Haemonetics Corporation
HAE
|
222 M | $ 59.53 | -0.05 % | $ 3 B | USA |
 |
Harvard Bioscience
HBIO
|
-48.6 M | $ 5.55 | 2.78 % | $ 246 M | USA |
 |
The Cooper Companies
COO
|
683 M | $ 71.73 | 2.97 % | $ 14.3 B | USA |
 |
iRhythm Technologies
IRTC
|
-57.4 M | $ 120.49 | 1.57 % | $ 3.86 B | USA |
 |
Isoray
ISR
|
-114 M | - | 0.03 % | $ 108 M | USA |
 |
Repro Med Systems
KRMD
|
-2.97 M | $ 4.19 | -1.18 % | $ 194 M | USA |
 |
Masimo Corporation
MASI
|
-267 M | $ 178.3 | -0.24 % | $ 9.5 B | USA |
 |
Microbot Medical
MBOT
|
-14.7 M | $ 2.35 | 2.62 % | $ 108 M |  Israel |
 |
Milestone Scientific
MLSS
|
-5.7 M | $ 0.27 | -4.66 % | $ 22.2 M | USA |
 |
Merit Medical Systems
MMSI
|
185 M | $ 69.24 | 2.73 % | $ 4.1 B | USA |
 |
electroCore
ECOR
|
-13.2 M | $ 6.21 | -7.45 % | $ 52.7 K | USA |
 |
Envista Holdings Corporation
NVST
|
216 M | $ 26.66 | 5.42 % | $ 4.48 B | USA |
 |
Pro-Dex
PDEX
|
10.7 M | $ 48.97 | -1.63 % | $ 161 M | USA |
 |
Glaukos Corporation
GKOS
|
-129 M | $ 118.62 | 3.09 % | $ 5.75 B | USA |
 |
Predictive Oncology
POAI
|
-181 M | - | - | $ 31.1 M | USA |
 |
ICU Medical
ICUI
|
42.8 M | $ 123.92 | 3.41 % | $ 3.05 B | USA |
 |
Intuitive Surgical
ISRG
|
2.95 B | $ 462.28 | 2.06 % | $ 165 B | USA |
 |
ResMed
RMD
|
1 B | $ 230.7 | 2.06 % | $ 33.7 B | USA |
 |
LeMaitre Vascular
LMAT
|
67.9 M | $ 112.41 | 1.89 % | $ 2.54 B | USA |
 |
Retractable Technologies
RVP
|
-21.2 M | $ 0.68 | -4.59 % | $ 20.4 M | USA |
 |
Pulse Biosciences
PLSE
|
-76.9 M | $ 19.06 | -4.51 % | $ 1.28 B | USA |
 |
STAAR Surgical Company
STAA
|
-91.7 M | $ 20.88 | -1.0 % | $ 1.03 B | USA |
 |
STERIS plc
STE
|
867 M | $ 225.03 | 2.65 % | $ 22.2 B | USA |
 |
Stereotaxis
STXS
|
-22.1 M | $ 1.93 | 4.32 % | $ 176 M | USA |
 |
NeuroMetrix
NURO
|
-8.78 M | - | 5.05 % | $ 9.02 M | USA |
 |
Teleflex Incorporated
TFX
|
13.9 M | $ 119.03 | 3.05 % | $ 5.31 B | USA |
 |
Utah Medical Products
UTMD
|
11.4 M | $ 64.53 | 1.67 % | $ 209 M | USA |
 |
West Pharmaceutical Services
WST
|
585 M | $ 265.93 | 2.54 % | $ 19.2 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
-422 M | $ 11.99 | 4.08 % | $ 2.39 B | USA |
 |
AngioDynamics
ANGO
|
-40 M | $ 10.17 | 4.85 % | $ 415 M | USA |
 |
Becton, Dickinson and Company
BDX
|
2.58 B | $ 157.09 | 1.37 % | $ 45.2 B | USA |
 |
Nephros
NEPH
|
-1.59 M | $ 2.91 | 4.68 % | $ 30.2 M | USA |
 |
OraSure Technologies
OSUR
|
-72 M | $ 3.08 | 0.65 % | $ 226 M | USA |
 |
Repligen Corporation
RGEN
|
47.7 M | $ 119.77 | 3.89 % | $ 6.67 M | USA |